Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?

United European gastroenterology journal - 1 Jun 2024

Tulone Adele, Pennisi Grazia, Ciccioli Carlo, Infantino Giuseppe, La Mantia Claudia, Cannella Roberto, Mercurio Francesco, Petta Salvatore

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD), with its steadily increasing prevalence, represents now a major problem in public health. A proper referral could benefit from tools allowing more precise risk stratification. To this end, in recent decades, several genetic variants that may help predict and refine the risk of development and progression of MASLD have been investigated. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Fatty Liver

Share to Genetic Testing

Share to Liver Cirrhosis

Share to Liver Neoplasms

Share to Non-alcoholic Fatty Liver Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 38659291
DOI: 10.1002/ueg2.12556
PMCID: PMC11176907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?PMID 38659291Read ↗

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity Read ↗

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read ↗

Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism.Semantic proximity Read ↗

Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association studySemantic proximity Read ↗

Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver BiomarkersSemantic proximity Read ↗

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.Semantic proximity Read ↗

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity Read ↗

Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity Read ↗

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read ↗

Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care.Semantic proximity Read ↗

Genetic Predisposition to MASLD: Potential for Therapeutic Management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.